u/draw_up_dizzy

the archive-after-a-year policy is deliberate

Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.

Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.

stretching the interval is not the same as reducing the dose

find the dose that holds, then stop optimising

Correcting myself: it was a quantity limit rather than a denial, which changes the whole process.

Have you asked the pharmacist to check?

Provincial plan, employer plan, or paying cash?

Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.

the shortage list is the whole legal hinge and people skip it

That is the 68-week readout, not the 72-week one.

This is the distinction that would end about half the arguments on this board.

Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.

Read the special authorization criteria and wrote the application against them line by line. Approved first time after a previous refusal.

registry entry, protocol, publication — three different documents

discontinuation rate is a result, not a footnote

Yes — nothing containing this is approved anywhere, which is the first fact and usually the last one mentioned.

find the dose that holds, then stop optimising

Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.

Agreed. The hepatic programme is the point of this compound and the weight discussion is a side effect of the side effect.

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.

Agreed — and the follow-up question is what the beyond-use date is based on.

Yes. Lean mass change during weight loss is expected; the useful question is the proportion, not whether it happens.

the label on a compounded vial is a legal document, read it

Cosigning on planning it in advance. Deciding what maintenance looks like while still losing is much easier than deciding it in a panic.

the ranking formula is published, go and read it

Small fix — you have described interval stretching and called it a dose reduction. The exposure profiles differ.

What does your weigh-in frequency look like at this point?

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth les

rohan_cardoso is right that stretching and reducing are different levers. Worth separating in every one of these threads.

This. The withdrawal data is not ambiguous and framing regain as a personal failure is both wrong and cruel.

Weigh monthly now. Best change I made in the whole run and it cost nothing.

Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.

What was the rate of weight change over that window?

the exception drug status route exists in several provinces

shortage status changes and the whole arrangement changes with it

vendor source pages link storefronts and the link is marked

This reframing is the most useful thing on the board for anyone approaching this phase.

Adding one thing — decide what maintenance looks like before you arrive at it.

Kept every form and reference number. When they had no record of a submission, I did.

maintenance is where the logistics finally get boring, which is the point